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Abstract
Background: Selective serotonin reuptake inhibitors are often used in alcohol use disorders. Clinical trials with selective 
serotonin reuptake inhibitors for alcohol use disorders, however, have yielded mixed results. The goal of this project was to 
assess whether a single i.v. dose of a selective serotonin reuptake inhibitor reduces craving for alcohol and/or simultaneously 
increases striatal dopamine concentration in individuals with alcohol dependence.
Methods: Alcohol-dependent (DSM-IV-TR criteria) volunteers and matched controls (n = 10/group) underwent a double-blind, 
placebo-controlled, within-subjects study. Participants received i.v. citalopram (40 mg) or saline (counter-balanced) followed 
by a cue-induced craving assessment and [18F]-fallypride positron emission tomography scanning.
Results: In the alcohol-dependent individuals, the citalopram (compared with saline) resulted in decreased cue-induced 
craving for alcohol. For the whole study group, cue-induced alcohol craving was inversely correlated with thalamic (but not 
striatal) dopamine D2/3 receptor availability.
Conclusions: Acute serotonin reuptake inhibition reduces cue-induced alcohol craving. Furthermore, thalamic dopamine 
abnormalities and the striatal hyperdopaminergic hypothesis of alcohol use disorder are supported.
Keywords: citalopram, antidepressant, alcohol, PET, craving
Introduction
Misuse of alcohol is a major global public health issue. Alcohol 
misuse remains extremely common in the United States, where 
it is estimated that roughly 6.4% of the population age 12 years 
or older meets criteria for alcohol use disorder (NSDUH, 2015), 
and alcohol misuse results in roughly 88  000 deaths per year 
(including alcohol-related motor vehicle accidents) (Stahre 
et al., 2014).
Alcohol use disorders are frequently comorbid with depres-
sive symptoms in psychiatric clinical populations, and the com-
bination results in an increased severity of both conditions, 
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including an increased risk for suicidality (reviewed in Nunes 
and Levin, 2004). Human and animal data have provided ample 
justification to test antidepressants in clinical trials for alcohol 
use disorders with (and without) comorbid depressive symp-
toms; however, results from these studies have been disappoint-
ing, especially with regard to continued alcohol use (Nunes and 
Levin, 2004; Kenna, 2010).
Citalopram, a highly selective selective serotonin reuptake 
inhibitor (SSRI), has been used clinically since 1989, is available 
in generic formulations, and is FDA-approved for the treatment 
of major depressive disorder (Bezchlibnyk-Butler et  al., 2000). 
The i.v. administration of serotonergic agents has been studied 
as a means to speed the time needed to remit depressive symp-
toms in patients with major depressive disorder (reviewed in 
Moukaddam and Hirschfeld, 2004).
In alcohol-dependent (AD) participants, visual and olfac-
tory cues reliably increase craving in a manner that is sensi-
tive to pharmacological and environmental manipulation (Ray 
et al., 2007). Cue-induced craving accompanies increased blood 
flow, specifically in the nucleus accumbens/ventral striatum in 
AD individuals, as an indirect measure of increased dopamine 
signaling, and this cue-induced craving is associated with lower 
baseline levels of dopamine D2/3 receptor availability (Heinz 
et al., 2004, 2005). Additionally, AD individuals, on average, have 
been shown to have lower striatal dopamine receptor D2/3 re-
ceptor availability than control participants, as measured with 
positron emission tomography (PET) and the dopamine D2/3 re-
ceptor radioligand [18F]-desmethoxyfallypride (Heinz et al., 2004)
Chronic oral citalopram (20  mg/d for 14  days) results in 
decreased striatal dopamine receptor binding potential com-
pared with placebo (using PET scanning and the dopamine 
D2/3 receptor ligand [
11C]-raclopride), an indication of increased 
intrasynaptic dopamine concentration, but a single dose of 
oral citalopram has not been shown to affect striatal dopamine 
binding potential (Tiihonen et al., 1996). A single i.v. infusion of 
citalopram (40  mg) decreased dopamine D2/3 receptor binding 
potential in the human striatum to a degree comparable with 
that seen in the earlier study of chronic oral citalopram dosing 
(Tiihonen et  al., 1996; Smith et  al., 2009). Therefore, we chose 
to study single-dose i.v. citalopram administration to test for 
SSRI-induced changes in cue-induced craving for alcohol and 
concomitant dopamine signaling in subcortical regions in AD 
research participants compared with matched healthy non-
drinking control participants.
METHODS
Overview of Study Procedures
All procedures were approved by the Veterans Administration 
Greater Los Angeles institutional review board. Participants 
were enrolled and screened on the first visit. Qualifying partici-
pants were invited back for 3 subsequent visits: a structural MRI 
scan and 2 study medication/[18F]-fallypride PET scanning days 
(citalopram 40 mg i.v., or saline placebo, double-blinded, admin-
istered in counter-balancing order) more than 1 week apart. All 
completing participants had breathalyzer-confirmed exhaled 
alcohol concentration of 0 and alcohol withdrawal scores 
(confirming no intoxication and minimal alcohol withdrawal 
symptoms) on all study visits (Clinical Institute Withdrawal 
Assessment for Alcohol [CIWA] < 10). On study medication/PET 
scanning days, the following procedures were completed in 
order: (1) breathalyzer, withdrawal, and psychiatric symptom-
atology screening; (2) i.v. citalopram (or saline placebo) infusion 
(1 hour); (3) cue-induced craving assessment (approximately 
20 minutes); and (4) [18F]-fallypride PET scanning (approximately 
3 hours). Smoking was allowed during study days but proscribed 
for 2 hours prior to PET scanning.
Research Participants
AD and healthy control (HC) participants were screened via the 
SCID-IV, excluding any participants with any Axis I psychiatric 
diagnosis within the last 6 months (aside from nicotine depend-
ence in both groups and alcohol dependence in the AD group). 
Fourteen potential AD and 17 potential HC participants were 
enrolled and screened. Ten participants in each group completed 
the study. Alcohol dependence in potential participants was 
confirmed using the SCID-IV diagnostic criteria. AD participants 
were active drinkers with no history of complicated alcohol 
withdrawal symptoms who agreed to stop drinking by 6:00 pm 
on the day prior to all study procedure days; significant alcohol 
withdrawal symptoms on study procedure days (CIWA > 10) was 
exclusionary. Inclusion criteria included age 21 to 55 years and 
no recent use (last 30  days) of any psychoactive medications. 
All participants had a normal physical exam, EKG, and labora-
tory studies, along with negative alcohol breathalyzer and saliva 
toxicology screens for opiates, benzodiazepines, amphetamine, 
cocaine, and cannabinoids on study days. Of the participants 
who completed the study, 7 AD and 6 HC participants had ana-
lyzable PET scan data due to technical PET scanning issues (PET 
scanner malfunction or radiosynthesis failure).
Assessments
Baseline rating scales included the Beck Depression Inventory-II 
to test for current depression/suicidality (Beck and Steer, 1996) 
and the CIWA (Sullivan et al., 1989; score <10 needed on all study 
days to ensure safe participation). Recent (last 90 days) average 
alcohol intake was assessed using the Timeline Follow Back 
assessment (Sobell et al., 1996). Craving for alcohol was assessed 
using the Alcohol Urge Questionnaire (AUQ) (MacKillop, 2006).
Intravenous Citalopram Infusions
Intravenous citalopram (Seropram) was provided by Lundbeck 
(Copenhagen, Denmark). On infusion days, participants received 
40 mg i.v. citalopram or saline placebo in a double-blinded man-
ner, followed by the assessments described below. Citalopram 
and counter-balanced saline placebo was infused in 250 mL of 
normal saline over 1 hour by infusion pump on separate scan-
ning days. Two to 3 hours after the infusion was completed, 
participants underwent PET scanning. PET scans were acquired 
after administration of 5 mCi of [18F]-fallypride, in two 80-minute 
blocks separated by a 20-minute break. The mean (SD) dose of 
[18F]-fallypride received by participants was 4.96 (0.20) mCi. 
Participants returned at least 1 week later to complete the 
second infusion/PET scan, counter-balanced. They completed 
the study after the second infusion/PET scan day.
Cue-Induced Craving Assessment
Cue reactivity was assessed after each of the intravenous infu-
sions (i.e., citalopram 40  mg or saline control) and followed 
standardized procedures as described (Monti et  al., 1987; Ray 
et al., 2007). After each period, craving was assessed using the 
AUQ. The mean of the 3 AUQ determinations was used as a 
covariate in further data analysis to compare with PET results. 
Craving scores were assessed by repeated-measures ANOVA.
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MRI and PET Scans and Analyses
Details of research structural MRI scans (acquired on a 3-T 
Siemens tomograph) and [18F]-fallypride (approximately 5 mCi) 
PET scans have been described previously (Okita et al., 2016a). 
[18F]-fallypride was synthesized in the cyclotron facility of the VA 
by procedures described previously (Lee et al., 2009), supported 
by an Investigational New Drug application (no.  78  226) from 
the FDA. Each batch of radiotracer was tested for quality con-
trol, including radiochemical purity, specific activity, and apyro-
genicity. All complete scans were analyzed for all subjects, with 
the result being that no partially completed studies (e.g., having 
only one PET scan for a given subject) were available.
PET Volume of Interest (VOI) and Whole-Brain 
Voxelwise Analysis
Reconstructed PET data were automatically segmented into 
standardized subcortical VOIs, and VOI binding potential (BPND) 
was estimated using the simplified reference tissue modeling 
with the cerebellum as the reference region via PMOD Kinetic 
Modeling (PMOD Technologies Ltd., Zurich, Switzerland) (see 
Okita et al., 2016a, 2016b for more detail). VOIs were established 
for the following brain regions: striatum (caudate nucleus, pu-
tamen, and nucleus accumbens as separate VOIs), amygdala, 
hippocampus, globus pallidus, and thalamus.
Correlation analyses for region-specific dopamine D2/3 
receptor BPND and mean cue-induced craving were done using 
Spearman rank coefficient testing. A  further test of the asso-
ciation between cue-induced craving and regional BPND (group 
× BPND interaction) was conducted with a whole-brain voxel-
wise analyses. Voxelwise parcellation of BPND estimation was 
done using FSL. ANOVA for effect of craving and group was done 
using SPM12 (Friston, 2007). All whole-brain voxelwise BPND sta-
tistics were computed with a voxel height threshold of F = 86.5 
(P < .0001), minimum cluster size of n = 20 voxels, and family-
wise error correction of P  <  .0001 for correction for multiple 
comparisons.
RESULTS
Demographics
The AD and HC groups did not differ in mean age (38 [7.6] vs 41 
[7.9] years, P = .38), sex distribution (8/10 vs 5/10 males, P = 0.44), 
fraction of ethnically white individuals (5/10 vs 4/10, P  =  .52), 
years education (12.9 [1.5] vs 13.8 [1.4], P  =  .2), or intake Beck 
Depression Inventory (9.5 [8.1] vs. 3.9 [4.2], P  =  .08). Therefore, 
subsequent analyses were not adjusted for demographic or clin-
ical variables that did not differ between study groups. Seven AD 
participants but none of the HC participants were current smok-
ers (though 7 of the HC group were former smokers; P =  .003). 
Current smoking and AD status were highly collinear, as smok-
ing is highly prevalent in individuals with alcohol dependence; 
therefore, smoking status was excluded from subsequent analy-
sis (Grant et al., 2004). AD participants reported consuming 6.9 
(2.3) drinks per day on average in the 90  days prior to study 
entry, whereas HC participants reported consuming 0.1 (0.14) 
drink per day (P < .0001).
Cue-Induced Alcohol Craving: Effect of i.v. 
Citalopram
Cue-induced alcohol craving was decreased by a single infusion 
of i.v. citalopram compared with saline placebo in AD partici-
pants (P = .003). Notably, there was a low baseline level of cue-
induced craving for alcohol in HC participants, and it tended 
to decrease with i.v. citalopram as well, compared with saline 
placebo (P =  .06). There was no group × citalopram interaction 
(F(1,17) = 1.28; P = .27).
Thalamic Dopamine D2/3 BPND Levels in AD 
Participants
Using ANOVA, there was a strong trend to decreased thalamic 
(but not striatal) dopamine D2/3 BPND in AD participants com-
pared with HC participants (2.7 vs 2.1; uncorrected P = .014; see 
Table 1). However, after Bonferroni correction for multiple com-
parisons, the group difference in thalamic 18F-fallypride BPND 
did not meet P  =  .05 significance criteria (Table 1). No overall 
effect of condition (i.v. citalopram vs saline placebo) on regional 
BPND was found (Table 1), although a trend to reduced BPND is 
seen in the thalamus (P = .06 uncorrected).
Correlations between Cue-Induced Alcohol Craving 
and D2/3 BPND
There was a strong correlation between mean cue-induced 
craving for alcohol and thalamic D2/3 BPND across all participants 
and conditions, even after correction for multiple comparisons 
(P = .0003 uncorrected; Figure 1A). There were no correlations be-
tween mean cue-induced craving for alcohol and region-specific 
BPND values in other regions tested.
Whole-brain voxelwise BPND analysis with mean cue-induced 
craving for alcohol as a covariate demonstrates strong correlations 
in bilateral thalamic regions (P < .0001), with weaker correlations 
Table 1. D2/3 Receptor Binding Potential ANOVA Results
Region
Group Condition
F value P value F value P value
Amygdala 0.01 .92 0.09 .77
Caudate 1.07 .32 0.98 .34
Hippocampus 0.96 .35 0.92 .36
Nucleus accumbens 0.03 .87 2.02 .18
Pallidus 3.55 .09 1.56 .24
Putamen 1.70 .22 0.87 .37
Thalamus 8.62 .01 4.47 .06
F and P values indicate ANOVA results for region BPND for group and condition effects. Condition = saline vs citalopram. Listed P values are uncorrected. After Bonfer-
onni correction for multiple comparisons, none of the P values fall below the P < .05 significance threshold.
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in other subcortical regions, across conditions (Figure 1B). 
There were also weaker signals for bilateral amygdalae, and left 
stronger than right Brodmann’s Area 38 cortical regions.
Discussion
Single-Dose i.v. Citalopram Reduces Cue-Induced 
Alcohol Craving
The results demonstrate that a single infusion of i.v. citalopram 
(40  mg) reduces cue-induced alcohol craving. Although many 
studies have shown the potential for a differential response to 
SSRIs in subtypes of AD individuals (“type I vs II” and “type A vs B”; 
Kenna, 2010), all of our participants had less craving for alcohol in 
the citalopram than the placebo condition. Given that there was 
no association between changes in dopaminergic neurotransmis-
sion and changes in cue-induced craving for alcohol, it is likely 
that the mechanism of action of single-dose i.v. citalopram crav-
ing attenuation is independent of changes in striatal dopamine.
No Effect of Single-Dose i.v. Citalopram on Striatal 
BPND as Assessed by Fallypride PET Scanning
Although a prior study with [11C]-raclopride showed that a 
single dose of i.v. citalopram decreased striatal dopamine re-
ceptor availability significantly, albeit only by approximately 
5% (Smith et al., 2009), the current results showed not even a 
trend for a change in striatal BPND with i.v. citalopram, as meas-
ured with [18F]-fallypride PET scanning (Table 1). However, given 
the relatively lower affinity of [11C]-raclopride for dopamine D2/3 
receptors compared with [18F]-fallypride, these results may be 
explained by pharmacology and neurophysiology (see following 
section for a more complete explanation).
Reduced Dopamine Receptor Availability in Alcohol 
Dependence: Thalamus in Fallypride Studies, 
Striatum in Raclopride Studies
Previous studies have shown mixed results when assessing 
whether AD individuals have lower striatal dopamine receptor 
availability than controls using various weakly binding PET ligands 
(such as [11C]-raclopride; cf Oberlin et al., 2015). However, one prior 
study showed that AD individuals at admission to a hospital pro-
gram had lower thalamic (but not striatal) dopamine D2/3 recep-
tor availability than controls using the PET ligand [18F]-fallypride 
(Rominger et al., 2012). Similarly, our study demonstrates a strong 
trend that actively drinking AD participants have lower thalamic 
dopamine D2/3 receptor availability than comparison HC partici-
pants with [18F]-fallypride, consistent with findings in (Rominger 
et al., 2012). Although fallypride has a greater affinity for dopamine 
D2 receptors than D3 receptors, a prior finding that the thalamus 
contains a higher level of D3 receptors than D2 receptors indicates 
that some of the thalamic differences we have observed may actu-
ally represent reduced thalamic D3 receptors in alcoholics com-
pared with matched controls (Sun et al., 2012). Future studies may 
consider investigating both thalamic dopamine D2 and D3 receptor 
availability separately in alcohol use disorder.
Alcohol Use Disorder: Aberrant Striatal Dopamine 
Signaling?
Our results and prior studies described above are consistent with 
the notion that alcohol use disorder represents a striatal hyperdo-
paminergic state (Hirth et al., 2016). Autoradiographic studies of 
human postmortem brain tissue (corroborated by a rodent model 
for alcohol use disorder) demonstrate that individuals with al-
cohol use disorder do not differ from controls in striatal dopamine 
D2 receptor density or D2 mRNA levels but do have lower dopamine 
transporter density (Hirth et al., 2016). However, it should be noted 
that the findings of Hirth et al. (2016) may conflict with some ear-
lier animal and human postmortem findings. The possibility that 
striatal alterations in alcohol dependence are more likely due to 
increased dopamine release rather than reduced dopamine re-
ceptor availability is broadly consistent with the results of this 
study, but more studies are needed to confirm this hypothesis.
Correlation of Cue-Induced Craving for Alcohol With 
Thalamic Dopamine D2/3 Receptor BPND
Our finding of a strong correlation between cue-induced crav-
ing for alcohol and thalamic dopamine D2/3 receptor availability 
in a group of AD and HC individuals is novel. Thalamic dopa-
mine signaling has been little-studied in the field of alcohol 
Figure 1. Thalamic dopamine binding potential (BPND) correlates with mean cue-induced craving scores in alcohol-dependent (AD) and healthy control (HC) subjects. 
Correlation between thalamic dopamine BPND and mean scores of cue-induced craving (Alcohol Urge Questionnaire [AUQ]). (A) Region-specific volume of interest (VOI) 
correlations. Group = participant group; cond = condition (active- citalopram, saline- placebo). Red indicates AD participants, blue indicates HC participants, circles 
indicate citalopram, triangles indicate saline. Diagonal line indicates linear correlation (coefficient r = −0.59) across conditions and participant groups. (B) Heat map of 
voxelwise correlation between dopamine D2/3 receptor BPND and mean cue-induced craving. Coronal section at z = 7 mm representing a map of mean voxelwise correl-
ation between dopamine D2/3 receptor BPND and mean cue-induced craving. Average voxelwise binding was warped into a sample participant MRI for demonstration 
purposes. Colors correspond to the F value of relevant voxelwise correlations, with strongest correlations seen in the bilateral thalamus (F values > 3000) after family-
wise error correction of P < .0001 for multiple comparisons.
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use disorders. However, the results presented here, combined 
with the earlier demonstration that AD individuals had lower 
thalamic dopamine D2/3 receptor availability than controls, 
should stimulate future studies on the role of aberrant thalamic 
dopamine signaling in alcohol use disorders (Rominger et  al., 
2012). Interestingly, these results parallel those of a prior study 
showing that methylphenidate-induced craving for cocaine in 
cocaine-dependent subjects was also correlated with reduced 
thalamic dopamine receptor availability, indicating that aber-
rant thalamic dopamine signaling may represent a more wide-
spread feature of substance use disorders (Volkow et al., 1997).
Limitations
A limitation of the study is the modest sample size, which was 
(at least partly) due to the detailed study methods (including 
2 full day sessions, including PET scanning, per participant). 
Another limitation was that, due to the extensive collinearity be-
tween smoking and alcohol dependence in the sample, we were 
unable to effectively disentangle any specific effect of smoking 
status on any of the measures reported. Additionally, we did not 
keep track of smoking behavior on study days of our smoking 
participants (aside from proscribing smoking for 2 hours prior 
to PET scanning), which may have influenced dopamine binding 
potential measurements. We did not keep track of the last drink 
consumed by participants prior to study procedures, though all 
participants were breathalyzer-negative during all procedures. 
Our samples represent approximately equal numbers of males 
and females and therefore may obscure any gender-specific 
effect on any of the reported measures. We excluded partici-
pants with active psychiatric illness and those taking psycho-
active medications; thus, these findings may not generalize to 
clinical samples of patients with alcohol use disorder where 
psychiatric comorbidities are common.
Conclusions
A single dose of i.v. citalopram reduces cue-induced craving for 
alcohol in AD participants. As noted above, it is unlikely that 
our observed decrease in cue-induced craving with a single dose 
of i.v. citalopram is due to any changes in brain dopamine re-
lease. Cue-induced craving for alcohol is highly correlated with 
thalamic dopamine D2/3 receptor availability in a mixed group of 
AD and HC research participants. The overall results are broadly 
consistent with the striatal hyperdopaminergic hypothesis of al-
cohol dependence, whereby increased dopamine release, rather 
than reduced postsynaptic dopamine receptor activity, is likely 
to be the major striatal dopaminergic neurochemical alteration.
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